GSK announces a groundbreaking $30 billion investment in the U.S. as President Trump visits the U.K. This commitment aims to enhance biopharma manufacturing and research, promising advancements in drug discovery and healthcare innovation.
Eli Lilly announces a groundbreaking $5 billion investment in a new manufacturing plant near Richmond, aimed at boosting U.S. production of essential pharmaceutical ingredients.